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EXAFSBacterial bioﬁlms cause a range of problems in many areas and especially in health care. Bioﬁlms are difﬁcult to
eradicate with traditional antibiotics and consequently there is a need for alternative ways to prevent and/or
remove bacterial bioﬁlms. Furthermore, the emergence of antibiotic resistance in bacteria creates a challenge
to ﬁnd new types of antibiotics with a lower evolutionary pressure for resistance development. One route to
develop such drugs is to target the so called virulence factors, i.e. bacterial systems used when bacteria infect a
host cell. This study investigates synergy effects between Ga(III) ions, previously reported to suppress bioﬁlm
formation and growth in bacteria, and salicylidene acylhydrazides (hydrazones) that have been proposed as
antivirulence drugs targeting the type three secretion system used by several Gram-negative pathogens, includ-
ing Pseudomonas aerugionosa, during bacterial infection of host cells. A library of hydrazones was screened for:
Fe(III) binding, enhanced anti-bioﬁlm effect with Ga(III) on P. aeruginosa, and low cytotoxicity to mammalian
cells. The metal coordination for the most promising ligand, 2-Oxo-2-[N-(2,4,6-trihydroxy-benzylidene)-
hydrazino]-acetamide (ME0163) with Ga(III) was investigated using extended X-ray absorption ﬁne structure
spectroscopy as well as density functional theory. The results showed that Ga(III) chelates the hydrazone with
5- and 6-membered chelating rings, and that the Ga(III)–ME0163 complex enhanced the antibioﬁlm effect of
Ga(III) while suppressing the type three secretion system in P. aeruginosa. The latter effect was not observed
for the hydrazone alone and was similar for Ga(III)–citrate and Ga(III)–ME0163 complexes, indicating that the
inhibition of virulence was caused by Ga(III).
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
Bioﬁlm is a bacterial growth mode characterized by formation of
organized cell clusters coated with extracellular polymeric substances.
According to National Institute of Health bioﬁlms are responsible for
up to 80% of all infections, which often become chronic and difﬁcult to
eradicate [1]. Extracellular polymeric substances enable bacteria to at-
tach to surfaces e.g. prosthetics, catheters, and tissues, and protect
them from antibiotics and host immunity. Another explanation
for bioﬁlm persistence and resistance to antibiotics is the slowermetab-
olism and distinct gene expression of sessile bacteria in bioﬁlms
compared to their planktonic, free-swimming, counterparts [2–4].46 90 786 7655.
46 90 786 7655.
(O. Rzhepishevska),
. This is an open access article underAmong bacteria that cause bioﬁlm-associated infections Pseudomonas
aeruginosa is one of themost ubiquitous. P. aeruginosa is an opportunistic
human pathogen causingmany types of infection e.g. in burnwounds [5],
and immunocompromised patients [6,7]. It causes life-threatening
pneumonia in cystic ﬁbrosis patients [8] and is one of the most common
pathogens infecting foot ulcers in patients with diabetes mellitus,
resulting in frequent foot and leg amputation [9]. Multi-drug resistant
P. aeruginosa strains represent a serious problem in healthcare with no
effective antibiotic treatments available. Thus, the need for new antimi-
crobial drugs and targets for treatment of these multi-resistant strains is
urgent and should not be underestimated.
Pathogens such as P. aeruginosa, Francisella tularensis, andMycobac-
terium tuberculosis are very sensitive to Fe limitation since Fe plays an
important role in the active center of many of their enzymes and respi-
ratory proteins [10–12]. Consequently, limiting Fe(III) availability is an
efﬁcient method used by the human body to control infection [13,14].
In mammalian body ﬂuids the level of free iron is very low as it isthe CC BY license (http://creativecommons.org/licenses/by/3.0/).
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ﬁnity to Fe(III) (binding constants log K ~20) [13,15]. The levels of
free Fe in different ﬂuids vary between individuals and time points
but in a study of 50 healthy adults it was found that the non-protein
bound Fe concentration was between 0 and 18 μM in plasma,
0–14 μM for amniotic ﬂuid, 0–11 μM for bronchoalveolar lavage and
0–0.59 μM for brain tissue with median values of 1.8 μM, 1.45 μM,
0.50 μM and 0.08 μM respectively [16]. Limitation of Fe has been
shown to prevent and disperse bioﬁlms in P. aeruginosa. Bacteria in
the depth of a bioﬁlm are starved due to Fe restriction, and dispersal
has been suggested through induction of twitching motility [17,18].
Fe(III) restriction can also be achieved through the addition of Fe(III) an-
tagonists. Ga(III) is an Fe(III) mimetic that is proposed to be taken up
into bacterial cells through Fe(III) transport mechanisms such as
siderophores and thereafter interfere with metabolic systems requiring
Fe(III) [19]. Exposure of P. aeruginosa to Ga(III) has been shown to inhib-
it bacterial growth and bioﬁlm formation [20–22].
The hydrazone substances, investigated, here have in common a
chelating motif in the center of the molecule that can bind metal ions
such as Fe(III) and Ga(III) (Fig. 1). Substances with similar chelating
motif have been tested as Fe(III) chelators for treatment of Fe(III)
overload in patients due to their high binding constants to Fe
[23–25]. Additionally, hydrazones were shown to inhibit type III
secretion system (T3SS) in a range of Gram-negative bacteria [26].
T3SS is a protein complex used for delivery of bacterial toxins into
the host cell, and it is a virulence factor that enables the pathogen
to infect a host and cause disease. Inhibiting T3SS prevents toxin
delivery and, hence, makes bacteria less harmful. The mechanism
of action for anti-virulence hydrazones is still to a large extent
unknown. Recent studies have shown that these compounds bind
to several proteins, suggesting multiple targets in the bacterial cell
[26,27]. Fe chelation by hydrazones has been shown to inhibit
growth and T3SS in sexually transmitted pathogens (Chlamydia
trachomatis and Neisseria gonorrhoeae) [28]. The involvement of Fe
in the expression of T3SS in these species is unclear while in other spe-
cies, Fe depletion stimulates the expression of T3SS through genetic cas-
cades [29]. Hydrazones have also been described to restrict Fe from
mammalian tumor cells and it was observed that treatment of tumor
cells with a combination of hydrazones and Ga(III) enhanced the effect,
indicating possible synergies [30–34].
In this study we screened Fe(III) chelating hydrazones, described
earlier [26], in the presence of Ga(III) ions and show that the antibacte-
rial and anti-bioﬁlm effects were enhanced. The presence of a Ga(III)–
hydrazone complex was evidenced from extended X-ray absorptionNH2
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Fig. 1. Chemical structure of two metal chelating hydrazone compounds: a) 2-Oxo-2-[N-
(2,4,6-trihydroxy-benzylidene)-hydrazino]-acetamide (ME0163), b) 3-(4-Hydroxy-
phenyl)-propionic acid (2,4,6- trihydroxy-benzylidene-)hydrazide (ME0161). A full list
of structures for the screened compounds can be found in Dahlgren et al. [26].ﬁne structure (EXAFS) spectroscopy, which shows that Ga(III) binds to
the chelating motif in the hydrazone.2. Methods
2.1. Chemicals
Chemicals were purchased from Sigma-Aldrich and used without
puriﬁcation unless otherwise stated. Hydrazones were synthesized
according to Dahlgren et al. [26] and Nordfelth et al. [35]. All solu-
tions were prepared from deionized and boiled water (resistance =
18.2 MΩ) at an ionic strength of 0.1 M NaCl (Merck p.a., dried at 453 K).
A 30 mM HCl solution in 0.1 M NaCl was made from concentrated HCl
(37% Aldrich) and standardized against tris(hydroxymethyl)
aminomethane (Trizma base). A 10 mM NaOH solution in 0.1 mM NaCl
(degassed with N2(g)) was made from a 50% NaOH solution and stan-
dardized against the standardized HCl solution. A 10.6 mM Ga(NO3)3
solution was prepared from Ga(NO3)3xH2O (Aldrich) in 0.1 M NaCl and
40.5 mM NaOH, giving Ga(III) in the form of the soluble Ga(OH)4− ion.
The exact concentrationofGa(III)was determinedbyusingAtomAbsorp-
tion Spectrometry (Perkin Elmer AAS 3110).2.2. Solubility screening
Hydrazone precipitation in aqueous solutionwas screened to identi-
fy which compounds would be soluble during the experimental condi-
tions for the study. For this, 100 μM solutions of hydrazones in ISO-
SENSITEST medium were incubated at room temperature for 24 h and
the turbidity of the solutions was measured at 600 nm. Screening for
Fe(III) binding can be found in supporting material.2.3. Bacterial growth conditions and bioﬁlm experiments
P. aeruginosa, PAO1,was routinely cultured on blood agar plates. ISO-
SENSITEST broth and tryptic soy broth (TSB) were used when growing
bacteria in liquid cultures. Iron-free medium was prepared according
to Rzhepishevska et al. [21] with small modiﬁcations. Standard ISO-
SENSITEST (100%)wasused and the concentrations of the trace element
solutions were adjusted to the following ﬁnal concentration: 0.03 mM
MgSO4; 0.08 μM ZnCl2; 0.01 μM CuSO4; 0.05 μMMnCl2; 0.25 μM CaCl2.
Minimal inhibitory concentration (MIC) that suppresses 90%
of bacterial growth (MIC90) of Ga(III) 2-Oxo-2-[N-(2,4,6-trihydroxy-
benzylidene)-hydrazino]-acetamide (Ga(III)–ME0163) was mea-
sured as described by Rzhepishevska et al. [21] and inhibition of
P. aeruginosa bioﬁlm formation was assessed by two methods. Method
one: P. aeruginosa PAO1 expressing green ﬂuorescence protein (GFP)
was used for screening bioﬁlm inhibition [26]. Bacteria were cultured
in multi-well plates with shaking in the presence of Ga–hydrazone
complexes. Growth was measured as culture absorbance at 600 nm
(OD600) after the medium with planktonic bacteria was carefully
removed. The amount of bioﬁlm was measured as a ﬂuorescent signal
from GFP at 515 nm. No washing step was included to avoid loss of
loosely attached bioﬁlm. Method two: to conﬁrm screening results
we used a standard crystal violet staining assay. Brieﬂy, 1 ml of ISO-
SENSITEST broth containing Ga(III)–citrate, Ga(III)–ME0163, and
ME0163, was inoculated with overnight culture of P. aeruginosa PAO1
and incubated in a humidiﬁed shaker at 37 °C. Crystal violet solution
(0.1%) was added to each well of a 24-well plate, incubated for 10 min,
rinsed with phosphate buffered saline (PBS) and air dried. Crystal violet
was dissolved in 33% acetic acid and absorbance of the solutions was
measured at 595 nm. The bioﬁlm assay was done in 20% ISO-
SENSITEST with the addition of tetracycline 10 μM to support the plas-
mid for GFP expression.
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To evaluate cytotoxicity and the inﬂammatory response of mam-
malian cells to 4-Methyl-[1,2,3]thiadiazole-5-carboxylic acid (6-
bromo-2-hydroxy-3-methoxy-benzylidene)-hydrazide (ME0150),
3-(4-Hydroxy-phenyl)-propionic acid (2,4,6-trihydroxy-benzylidene-)
hydrazide (ME0161), ME0163 and 3-Methoxy-benzoic acid (3,5-di-
tert-butyl-2-hydroxy-benzylidene)-hydrazide (ME0184), we used
three different cell lines: BEAS-2B (human bronchial epithelial cells),
A549 (human alveolar epithelial cells) and L929 (mouse ﬁbroblast
cells). BEAS-2B cells were cultured in serum-free bronchial epithelial
cell basal medium with supplements (complete medium, BEGM
Cambrex,Verviers, Belgium). A549 and L929 cells were grown as previ-
ously described [21]. Cell viability/cytotoxicity was measured using the
AlamarBlue assay (Serotec Scandinavia, Kidlington, United Kingdom)
[21]. Stock solutions of ME0150, ME0161, ME0163 and ME0184 were
diluted in culture medium to a ﬁnal concentration of 10 μM, 50 μM,
100 μM and 200 μM and added to the cells in 8 replicates. Pro-
inﬂammatory cell response was analyzed by monitoring the release
of interleukin 8 (IL-8), and interleukin 6 (IL-6) using enzyme-linked im-
munosorbent assay (ELISA R&D Systems, Abingdon, United Kingdom)
[21].
2.5. EXAFS spectroscopy data collection and analysis
Samples for EXAFS were prepared by adding a high pH 10.6 mM
Ga(OH)4− solution and 10 mM NaOH solution into a solution of
hydrazone in 0.1 M NaCl under N2 atmosphere and stirring to give a
ﬁnal concentration of 1.74–1.95 mM (ratio Ga:ME0163 1.06:1). The
pH was adjusted using 30 mM HCl, which gave solutions with [Ga(III)]
= 2.07 mM and pH = 10.6 (N1), [Ga(III)] = 1.89 mM and pH = 8.9
(N2), and [Ga(III)] = 1.84 mM and pH = 7.9 (N3). The samples were
equilibrated for ﬁve days before EXAFS analysis. An aqueous paste of
amorphous Ga(OH)3(s) [36], an aqueous solutions of Ga(III)–citrate
[Ga(C6H5O7)23−] [37], andGa(OH)4− (10.6mMGa; pH 11.3)were select-
ed as EXAFS references. More detailed EXAFS method description and
data analysis can be found in supporting material.
2.6. Density functional theory (DFT) calculations
A geometry optimization of the neutrally-charged Ga(OH)21+–
H3L1−·H2O complex (where L−4 is the completely deprotonated
ME0163 ligand and Ga(III) is in 5- and 6-membered chelate coordina-
tion) was carried out at the B3LYP/6-31G level of theory [38]. A water
molecule was added to this complex to complete the octahedral coordi-
nation shell of Ga(III). Calculations were carried out using Gaussian 09
[39].
2.7. Induction and analysis of type three secretion system (T3SS)
T3SSwas induced by lowcalciumgrowth conditions (TSB brothwith
EGTA and 5 mM MgCl2) as described by Lee et al. [40]. P. aeruginosa
PAO1 was grown to OD600 of 1.9, bacteria were pelleted and culture
supernatant (1.8 ml) was used for analysis of the secreted proteins.
Secreted proteins were precipitated from supernatant by 10% trichloro-
acetic acid, washed with acetone and re-suspended in 100 μl loading
buffer for electrophoresis [33,41,42]. At the same time, aliquots of the
culture containing both bacteria and the supernatant (100 μl) were col-
lected and mixed with the loading buffer to analyze total (expressed
and secreted) protein. Protein fractions were separated on NuPAGE
ready-made gradient gels (Novex, Life Technologies) and ExoS protein,
a marker of T3SS expression and secretion, was detected usingWestern
blot with ExoS antibody. Total protein fraction was additionally ana-
lyzed using FliC (H7) antibody as a control of protein expression in
the presence of Ga(III) complexes at 50 μM (1:1 complex). All experi-
mental conditions (cultures, optical density measurements andsecreted protein analysis) were performed in triplicates. Total protein
was analyzed in duplicates.
3. Results and discussion
3.1. Hydrazone Fe(III) binding ability
A hydrazone collection of 54 compounds, obtained by statistical mo-
lecular design and subsequent synthesis [26], was screened with excess
hydrazone to assess Fe(III) binding (Table S2 in supporting material).
For most hydrazones, Fe(III) complexes were formed to different ex-
tents. For example, in the 1:2 Fe:hydrazone mixture used, ME0161
gave a 1:1 ratio between free ligand and complex indicating possible
formation of a 1:1 Fe:hydrazone complex. However, no Fe(III) complex
was detected for the hydrazoneME0163 under the experimental condi-
tions used.
3.2. Antibioﬁlm and antibacterial effects of Ga(III)–hydrazone complexes
Since complex formationwith Fe(III) varied for different hydrazones
(Table S2) it could be expected to vary also for Ga(III). Hence in the next
step the hydrazone library was screened for the most efﬁcient Ga(III)
complexwith respect to anti-bioﬁlm effects on P. aeruginosa. First, com-
pounds with good solubility in aqueous media were selected as we ob-
served that some hydrazones precipitated in these conditions.
Thereafter, 1:1 Ga(III):hydrazone mixtures at different concentrations
were studied for effect on growth and bioﬁlm formation of P. aeruginosa
(Fig. 2 and Fig. S1). A solution with Ga(III)–citrate complexes was used
as a reference since it has previously been reported to have both antibac-
terial and antibioﬁlm properties [21]. A large inhibition of planktonic
growth was seen for ME0150 and ME0184 at concentrations higher
than 6 μM (Fig. 2). An anti-bioﬁlm effect could be observed for most of
the tested compounds already at 3 μM of Ga(III)–hydrazone although
the effect was similar to that obtained with Ga(III)–citrate. ME0161
and ME0163 showed the largest antibioﬁlm effect at several different
concentrations, displayed an enhanced antibioﬁlm effect compared to
the Ga(III)–citrate control, and had little effect on growth (Figs. 1 and
2). The increased activity of ME0163 with Ga(III) suggested that it
could formmetal complexes even if an Fe(III) complexwas not detected
in the aforementioned Fe(III) binding assay.
3.3. Cytotoxic effects on human cells
For any application in medicine it is important that the substance is
not toxic to mammalian cells. The hydrazones alone have previously
been screened for toxicity to HeLa cells [26], but we were interested to
look into the toxicity of the hydrazones with and without Ga(III) to
epithelial cells (that could be expected to become exposed to these
substances were they to be used topically or on medical devices).
Consequently, we studied cytotoxicity and inﬂammatory response on
human bronchial epithelial cells (BEAS-2B), alveolar epithelial cells
(A549) and mouse ﬁbroblast cells (L929 — a common reference cell
line). CompoundsME0150 andME0184 that had a large effect on bacte-
rial growthwere also toxic tomammalian cells (Fig. S2) andwere there-
fore excluded from further investigations. However, compounds
ME0161 and ME0163 in the presence of gallium were not found to be
cytotoxic (Fig. S3) nor produce inﬂammatory responses when tested
on bronchial or alveolar cells (data not shown). No toxicity to bronchial
epithelial cells was seen even in the absence of serum, which is an im-
portant observation since serum has been reported to protect cells
from antibiotic toxicity by metal ions in vitro [43].
3.4. Antibioﬁlm and antibacterial effects of the complex Ga(III)–ME0163
After the screening we focused on ME0163 with Ga(III) as it had
better anti-bioﬁlm properties compared to Ga(III)–citrate, exhibited
Fig. 2. The combination effect of Ga(III) and different hydrazones (ratio 1:1, full names in
Table S1) on (from left) bioﬁlm formation (red bars) and growth of PAO1 in solution (blue
bars) tested at a concentration of a) 25 μM, b) 12.5 μM, c) 6.12 μM, and d) 3 μM in 20% ISO-
SENSITEST. Bioﬁlmwas judgedbyﬂuorescence of greenﬂuorescence protein expressed by
bacteria. “Control” is no Ga(III) or hydrazone and “Ga cit” corresponds to samples with
Ga(III)–citrate (previously shown to inhibit both growth and bioﬁlm formation [21]).
a)
b)
c)
Fig. 3. a) Bioﬁlm measured by crystal violet staining in 20% medium (from left): blue
control, green ME0163, red Ga(III)–citrate, orange Ga(III)–ME0163, y-axis shows ratio to
baseline control (no bacteria). b) Growth curves of PAO1 in the presence of Ga(III)–citrate
(red circles), ME0163 (inverted green triangles) and Ga(III)–ME0163 (orange triangles),
control (blue squares), empty symbols 12.5 μM and ﬁlled symbols 50 μM. All in 20% ISO-
SENSITEST. c). Growth curves of PAO1 in 100% ISO-SENSITEST (empty symbols) and che-
lated, iron-free ISO-SENSITEST (ﬁlled symbols) at 50 μM of Ga(III)–citrate (red circles),
Ga(III)–ME0163 (orange triangles), ME0163 (inverted green triangles), control (blue
squares).
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ME0163 enabled detailed thermodynamic studies of protonation and
metal binding (reported in Hakobyan et al. [44]). First, the data from
the bioﬁlm screeningwas conﬁrmed using a secondmethod, i.e. the tra-
ditional crystal violet assay. Both bioﬁlm assays showed that Ga(III)–
ME0163 inhibited bioﬁlm formation more efﬁciently at low concentra-
tions than Ga(III)–citrate did, while ME0163 alone had very little effect
on bioﬁlm formation (Fig. 3a). Bacterial growth curves showed that
Ga(III)–ME0163 inhibited growth of P. aeruginosa more efﬁciently
than Ga(III)–citrate at a concentration of 50 μM (Fig. 3b) while at 12.5
μM the inhibition was comparable between the two Ga(III) complexes.
These results are consistent with previous studies of Ga(III) showing
that lower concentrations of Ga(III) are needed to prevent bioﬁlm
formation than to inhibit growth [21]. Thus, the results indicate that
when used together with ME0163, the anti-bioﬁlm action of Ga(III) is
achieved at lower concentrations. At higher concentrations, e.g. 50 μM,
the difference in bioﬁlm inhibition becomes masked by growth
inhibition.
Since both compounds are described as Fe antagonists and themedi-
umdiluted to 20%will have a low amount of Fe, we also investigated theantibacterial effect in standard (100%) medium, that contains ~6–7 μM
Fe, and standard medium treated with Chelex-100, a resin that binds
free Fe. In standard ISO-SENSITEST MIC90 for both Ga(III)–ME0163 and
Ga(III)–citrate was 200 μM, but in Fe–free ISO-SENSITEST, MIC90 was
100 μM for Ga(III)–ME0163 and 200 μM Ga(III)–citrate. In Fe-free
5O. Rzhepishevska et al. / Journal of Inorganic Biochemistry 138 (2014) 1–8conditions 50 μM of ME0163 alone (Fig. 3c) inhibited growth of
P. aeruginosa to some extent, while it had no effect on growth in 20%
ISO-SENSITEST (Fig. 3b). In both Fe restricted conditions (Fig. 3b
and c) Ga(III)–ME0163 suppressed bacterial growth, indicating a syner-
gistic inhibitory effect between Ga(III) ions and ME0163, especially in
the Chelex-treated medium where Ga(III)–citrate had almost no effect
on growth. An explanation for this lack of inhibition fromGa(III)–citrate
could be that metabolic pathways for bacteria growing in chelated
media may differ. Together with iron, Chelex-100 also binds organic
compounds and concentrations of certain amino acids can be decreased
up to 80% in growth media due to chelation [45]. This may cause bacte-
ria to use another energy source (e.g. glucose) and express different en-
zymes. The alternative enzymes may be less affected by Ga(III) thereby
decreasing bacterial sensitivity to gallium [21].
The synergistic or additive effect of a Ga(III)–ME0163 complex could
be accounted for in several ways: i) the presence of Ga(III) and forma-
tion of a Ga(III) complex solubilizes Ga(III) and/or the hydrazone to a
larger extent or thereby increase the active concentration in solution
for both substances, ii) thehydrazone andGa(III) both act on Fe(III) sen-
sitive systems (e.g. enzymes) and therefore the effect is enhancedwhen
both substances are present, or iii) the complex has an increased effect
caused by differences in uptake or target. The enhanced synergy effect
in Fe-free conditions suggests that the ﬁrst explanation is unlikely as
the solubility should be similar or higher in the presence of Fe(III)
since complexation of ME0163 with Fe(III) as well as Ga(III) would
shift the solubility equilibrium towards soluble species. The second
and third explanation seems more probable. Explanation ii) is possible
since Fe(III) sensitive enzymes could be rescued at some base level of
Fe(III) in the medium, thus suggesting a reason for the difference be-
tween 20%and 100%media, however, this does not clarify the difference
between Ga complexes. The difference observed between Ga(III)–cit-
rate and Ga(III)–ME0163 in chelated medium could be accounted for
by hypothesis iii) and/or that the bacteria change carbon source in
Chelex-treated medium. We showed previously that P. aeruginosa
grown on glucose expresses approximately 4 times less pyoverdine
than P. aeruginosa grown on Casamino acids [21]. Consequently, if
P. aeruginosa loses the potent siderophore pyoverdine and free Fe(III)
is sequestered by ME0163, it may experience iron starvation. While
the mechanism of this process is outside the scope of this article, it is
clear that ME0163 is a successful ligand for Ga(III) potentiating its anti-
bacterial and anti-bioﬁlm effects in both types of medium, and that the
effect on bioﬁlm occurs at lower concentrations than the effect on bac-
terial growth. Furthermore, considering that the 20% medium had free
Fe levels corresponding to those measured in biological ﬂuids, we canb)a)
Fig. 4. a) Speciation diagramcalculated from formation constants [44] for EXAFS sampleN2 cont
complex showing distances from the DFT calculations.assume that the complex would still be effective in most biological
ﬂuids.
3.5. EXAFS analysis and DFT calculations of complex
The biological effects observed did not necessarily have to be a result
of a Ga(III)–ME0163 complex but could also have been a combined ef-
fect of the two substances acting alone on the bacterial cell, especially
since no Fe(III)–ME0163 complex was detected. However, a parallel
study [44] showed strong complex formation at physiological pH
(Fig. 4a), with hydrazone binding constants to Ga(III) similar to that of
EDTA. While those experiments were carried out under more dilute
conditions than those considered in this work, the thermodynamic
model generated in that study ought to be applicable to a wide range
of concentrations. As concentrated systems can generate multinuclear
species and/or solid phases that do not occur under more dilute sys-
tems, we made use of EXAFS and DFT calculations to conﬁrm that i)
Ga(III)–ME0163 complexation was effectively achieved and ii) to pro-
vide complementary characterization of the bonding environment of
Ga(III) and ME0163.
EXAFS data for a sample at pH 10.6 (N1) was successfully modeled
with only a ﬁrst coordination shell consisting of 3.9 O/N at a distance
of 1. 84 Å in accordance with the Ga–O distances in Ga(OH)4− (Fig. 5;
Table S3). Thus, at this pH there was no or only minor complex forma-
tion between Ga(III) and the hydrazone ligand and Ga(III) exists as a
soluble hydroxo-complex, in agreement with the thermodynamic
model in Hakobyan et al. [44] (Fig. 4a). For samples at pH 8.9 and 7.9
(N2 and N3) a model with 1 O/N distance in the ﬁrst shell resulted in
a poor ﬁt indicating a distorted ﬁrst shell or that several Ga(III) species
are present in the samples. The ﬁt was signiﬁcantly improved by intro-
ducing a second Ga–O/N distance and the two obtained distances
(1.83–1.85 Å and 1.95 Å) were in accordance with Ga–O distances in
four-coordinated Ga(OH)4− and in six-coordinated Ga(NO)3(aq). The
coordination number (CN) obtained for the longer Ga–O/N path was
higher in both of these samples suggesting that 6-coordinated Ga(III)
species dominated (Table S3) and illustrating a large change in Ga(III)
speciation as pH is decreased. Furthermore, at the lower–pH samples
Ga–C/N interactions were detected in the second coordination shell
showing that Ga(III) forms inner-sphere complexes with the hydrazone
ligand. The Ga–C/N distances obtained (2.95–2.96 Å) are fairly close to
Ga–C distances in Ga(III)–citrate (2.73–2.93 Å), where Ga(III) is com-
plexed by both 5- and 6-membered chelate rings [37], thus in a coordi-
nationmotif similar to that expected for the Ga(III)–hydrazone complex
(based on crystal structure of a Cu–hydrazone complex [46]) and,aining1.89mMGa(III); b) geometry of a representative neutrally-chargedGa(III)–ME0163
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Fig. 5. a) k3-weighted EXAFS spectra (solid lines) with ﬁt results (dotted lines) and b) corresponding Fourier transforms (solid lines) with ﬁt results (dotted lines) for the Ga-hydrazone
samples compared with references; (I) Ga(OH)4− (II) N1; 2.07 mMGa(III) and pH 10.6, (III) N2; 1.89mMGa(III) and pH 8.9 (IV) N3; 1.84mMGa(III) and pH 7.9 (V) Ga(OH)3(s) [36] and,
(VI) Ga(III)–citrate [37]. Vertical dashed lines highlight the peak position of the second oscillation in k-space for Ga(OH)4− and peak positions of the second coordination shells in the FT for
Ga(III)–citrate and Ga(OH)3(s).
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ble ligands available to coordinate Ga(III) in the EXAFS solutions were
H2O, OH− and ME0163, these data clearly indicate a direct interaction
between Ga(III) and the hydrazone in the lower–pH samples.
In an effort to constrain our understanding of this complex further,
DFT calculations were performed. We chose to study the neutrally-
charged Ga(OH)21+–H3L1−·H2O complex (where L−4 is the completely
deprotonated ME0163 ligand and Ga(III) is in 5- and 6-membered che-
late coordination, Fig. 4b), well noting that species of different Ga(III)-
hydrolysis and ligand-protonation states can very well give rise to dif-
ferent sets of atomic distances. The values for this neutrally-charged
species are therefore only representative of a range of values that can
be experimentally detected in a mixture of species. The resulting com-
plex had a ﬁrst coordination shell consisting of six Ga–O/N distances
in the 1.85–2.11 Å range, with an average at 2.00 Å, thus comparable
to EXAFS results. A second Ga–N distance lies at 2.90 Å, and a second
shell Ga–C distances in the 2.84–3.46 range, again comparable with
EXAFS results.
In addition to the Ga(III)–ME0163 complex, EXAFS also provided
evidence forGa–Ga interactionswith distances that are highly compara-
ble to those occurring in Ga(OH)3(s) (Table S3). Formation constants
from Hakobyan et al. [44] suggest that small amounts of GaOOH(s)
should be formed at pH lower than 8.5 at these Ga(III) concentrations
(Fig. 4a). However, it is possible that an amorphous Ga(OH)3(s) phase
was formed with a different solubility to the crystalline GaOOH(s)
used in speciation determinations in Hakobyan et al. [44]. The EXAFS
samples were analyzed ﬁve days after sample preparation whereas
the equilibrium data in Hakobyan et al. were determined at shorter
equilibrium times (4 h). Furthermore, the concentrations in the EXAFS
samples were higher (1.8 mM vs. 50 μM). Thus, it is possible that an
amorphous solid phase could have been formed after 5 days at the
higher concentrations in the EXAFS samples even if it did not form dur-
ing titrations at 50 μM described in Hakobyan et al. [44].3.6. Gallium complexes inhibit the expression of virulence factors
To study the induction and activity of T3SS in the presence of
ME0163 and Ga(III)–ME0163 we measured expression and secretion
of ExoS, a toxin secreted by the T3SS. Cultures of equal optical density
i.e. equal number of bacterial cells were used for all experimental condi-
tions. ExoS expression and secretion in the presence of ME0163 were
similar to control (Fig. 6a and b) which is in agreement with data ob-
tained with Yersinia pseudotuberculosis [26]. In contrast, both Ga(III)–
citrate and Ga(III)–ME0163 expression and secretion of ExoS dramati-
cally dropped to low or undetectable levels (Fig. 6a and b). Our conclu-
sion is that the T3SS is not completely shut down but strongly
suppressed in the presence of Ga(III) complexes. Previously, we have
observed an altered protein expression pattern in P. aeruginosa in the
presence of Ga(III) [21]. However, this is the ﬁrst report on suppression
of such an important virulence factor as T3SS by Ga(III) complexes. The
suppression is obviously selective as the levels of FliC protein in the same
sampleswere not changed. Selective inhibition of T3SS implies that even
though bacteria are able tomultiply at a given concentration of the com-
pound, their ability to damage the host cells is much weakened through
the presence of Ga(III).3.7. Conclusions
In this study we have shown that Ga(III) forms a complex with
the hydrazone ME0163 exhibiting two chelating rings. This Ga(III)–
ME0163 complex was found to have an enhanced anti-bioﬁlm effect
in low Fe(III) conditions but this effect disappeared in 100% ISO-
SENSITEST medium where Fe(III) was presumably present at high
enough levels to counteract the Fe antagonist effect. While ME0163
alone did not have a large effect on the T3SS in P. aeruginosa, we
observed that Ga(III)–ME0163 and Ga(III)–citrate suppressed expression
Fig. 6. Expression and activity of T3SS are speciﬁcally inhibited in the presence of
50 μM of Ga(III) complexes; a) presence of ExoS effector in the secreted protein fraction;,
b) presence of ExoS effector in the total protein fraction, c) presence of ﬂagellar structural
protein FliC in the total protein fraction. For all the experimental conditions aliquots for
protein analysis were taken at equal culture density to ensure the equal number of cells
in the sample.
7O. Rzhepishevska et al. / Journal of Inorganic Biochemistry 138 (2014) 1–8and secretion of the T3SS effector protein ExoS. To the best of our knowl-
edge, this work is the ﬁrst to present Ga(III) complexes that suppress the
T3SS in bacteria. Thus, this study opens up for new approaches to target
virulence in the form of T3SS in bacteria.
Abbreviations
ME0163 2-Oxo-2-[N-(2,4,6-trihydroxy-benzylidene)-hydrazino]-
acetamide
EXAFS extended X-ray absorption ﬁne structure
DFT density functional theory
T3SS type III secretion system
MIC90 minimal inhibitory concentration that suppresses 90% of bac-
terial growth
GFP green ﬂuorescence protein
ME0150 4-Methyl-[1,2,3]thiadiazole-5-carboxylic acid (6-bromo-2-
hydroxy-3-methoxy-benzylidene)-hydrazide
ME0161 3-(4-Hydroxy-phenyl)-propionic acid (2,4,6-trihydroxy-
benzylidene-)hydrazide
ME0184 3-Methoxy-benzoic acid (3,5-di-tert-butyl-2-hydroxy-
benzylidene)-hydrazide
IL-8 interleukin 8IL-6 interleukin 6
ELISA enzyme-linked immunosorbent assay
TSB tryptic soy broth
EGTA ethylene glycol tetraacetic acid
OD600 optical density at 600 nm
CN coordination number
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Appendix A. Supplementary data
Fe(III) binding assay, tablewith full names of ligands, detailed exper-
imental description of EXAFS analysis, table with distances from EXAFS
analysis of the Ga(III)–ME0163 complex, as well as additional ﬁgures
with results from growth and bioﬁlm formation assay, and mammalian
cell viability tests are all available free of charge via the internet. Supple-
mentary data associatedwith this article can be found in the online ver-
sion, at http://dx.doi.org/10.1016/j.jinorgbio.2014.04.009. These data
include MOL ﬁles and InChiKeys of the most important compounds de-
scribed in this article.
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